HPS2-THRIVE and the future of clinical endpoint trials
Prof.John Betteridge with a critical appraisal of the results of the HPS2-THRIVE trial and the relevance for clinical practice and design of future outcome trials.
Prof. D John Betteridge
Professor Emeritus of Endocrinology and Metabolism
University College London and Associate Dean, Royal Society of Medicine
London, United Kingdom